<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rheumatol Int</journal-id><journal-id journal-id-type="iso-abbrev">Rheumatol. Int</journal-id><journal-title-group><journal-title>Rheumatology International</journal-title></journal-title-group><issn pub-type="ppub">0172-8172</issn><issn pub-type="epub">1437-160X</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7103900</article-id><article-id pub-id-type="publisher-id">4570</article-id><article-id pub-id-type="doi">10.1007/s00296-020-04570-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1652-4648</contrib-id><name><surname>Georgiev</surname><given-names>Tsvetoslav</given-names></name><address><email>tsetso@medfaculty.org</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.460112.0</institution-id><institution>Clinic of Rheumatology, </institution><institution>University Hospital &#x0201c;St. Marina&#x0201d;, Medical University-Varna, </institution></institution-wrap>1, Hristo Smirnenski, 9010 Varna, Bulgaria </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>3</month><year>2020</year></pub-date><fpage>1</fpage><lpage>2</lpage><history><date date-type="received"><day>22</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>24</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions></article-meta></front><body><p id="Par1">To the Editor,</p><p id="Par2">Current pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2&#x000a0;(SARS-CoV-2). Despite drastic containment measures, the COVID-19 outbreak has taken lives of more than 12,000 people worldwide, with the number of those contracting the virus surpassing 300,000 (as of March 22, 2020) [<xref ref-type="bibr" rid="CR1">1</xref>]. The seriousness of the situation necessitates urgent multidisciplinary strategy to contain the spread of the disease and prevent its complications.</p><p id="Par3">The affection of the lower airways in severe COVID-19 is driven by uncontrolled immune-mediated inflammatory response. T lymphocytes are the main target cells in severe acute respiratory syndrome (SARS) due to COVID-19, triggering cytokine storm with subsequent exhaustion of immune response [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Importantly, there is no association between the viral load and severity of the disease [<xref ref-type="bibr" rid="CR4">4</xref>]. The cascade of the disease pathways is reminiscent of systemic immune disturbances, particularly those in severe rheumatic flare. Based on the current knowledge of COVID-19 pathophysiology and clinical manifestations, the rationale for searching specific antivirals along with immune-modulating drugs is justifiable. A quick search through the US National Library of Medicine Clinical Trials registry (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link>) and the Chinese Clinical Trial Registry (<ext-link ext-link-type="uri" xlink:href="https://www.chictr.org.cn">https://www.chictr.org.cn</ext-link>) may help retrieve links to studies of anti-rheumatic drugs in COVID-19. Ongoing research brings about hope for developing evidence-based anti-rheumatic therapies for the viral disease.</p><p id="Par4">Systemic corticosteroids (CS) are known to potently dampen immune inflammation. Like in inflammatory rheumatic diseases, CS might serve as a &#x0201c;bridge&#x0201d; to specific efficient antiviral therapy for COVID-19. Despite the common fears of the virus replication, provisional recommendations for managing excessive inflammatory response in COVID-19 include intravenous CS [<xref ref-type="bibr" rid="CR5">5</xref>]. The World Health Organization (WHO), however, recommends to avoid routine administration of systemic CS for the treatment of viral pneumonia outside clinical trials [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par5">Chloroquine (CQ) and its less toxic derivative hydroxychloroquine (HCQ) are well known for their immunomodulating effects in rheumatology. For decades, these drugs have been used for the treatment of systemic lupus erythematosus and rheumatoid arthritis. The justification for their use in COVID-19 is largely based on the knowledge of their intracellular action [<xref ref-type="bibr" rid="CR7">7</xref>]. These antimalarial drugs may disrupt the virus replication and subsequent cytokine storm in severe COVID-19 [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. CQ has proved efficient against the virus in COVID-19 pneumonia in Chinese clinical trials, justifying the inclusion of the drug in the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 [<xref ref-type="bibr" rid="CR10">10</xref>]. An open-label non-randomized clinical trial by Gauret et al. showed that HCQ reduces viral load in most COVID-19 patients and that its efficacy is enhanced in combination with azithromycin [<xref ref-type="bibr" rid="CR11">11</xref>]. HCQ low costs and relative safety profile may secure its place in the strategy against COVID-19 [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par6">Interestingly, interleukin(IL)-6 levels are significantly elevated in severe COVID-19, suggesting its crucial role in cytokine storm and predicting adverse outcomes [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. IL-6 levels are associated with SARS-CoV-2 viral load [<xref ref-type="bibr" rid="CR15">15</xref>]. Blocking IL-6 receptor might be a promising strategy in the disease management. Preliminary evidence from a small uncontrolled trial in China proves that tocilizumab in addition to routine therapy is effective for decreasing C-reactive protein levels and alleviating symptoms. Tocilizumab therapy is listed in the recommendations for severe COVID-19 management by the National Institute for the Infectious Diseases&#x000a0;&#x02018;Lazzaro Spallanzani' [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par7">The recent advances in the understanding of COVID-19 have pointed to the similarities of the cytokine storm syndromes in this viral disease and inflammatory rheumatic disorders, justifying the use of anti-rheumatic drugs in both conditions. Rheumatologists should share their experience with managing patients with rheumatic disorders and join the global multidisciplinary fight against COVID-19.</p></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="ethics"><title>Compliance with ethical standards</title><notes notes-type="COI-statement"><title>Conflict of interest</title><p id="Par8">Tsvetoslav Georgiev declares that he has no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">World Health Association (2020) Coronavirus disease 2019 (COVID-19) situation Report&#x02014;61. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200322-sitrep-62-covid-19.pdf">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200322-sitrep-62-covid-19.pdf</ext-link>. Accessed 22 Mar 2020</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Tai</surname><given-names>Y</given-names></name></person-group><article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title><source>Lancet Respir Med</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30076-X</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Ruan</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Hong</surname><given-names>Z</given-names></name><etal/></person-group><article-title>SARS-CoV-2 viral load in upper respiratory specimens of infected patients</article-title><source>N Engl J Med</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMc2001737</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicastri</surname><given-names>E</given-names></name><name><surname>Petrosillo</surname><given-names>N</given-names></name><name><surname>Ippolito</surname><given-names>G</given-names></name><name><surname>D&#x02019;Offizi</surname><given-names>G</given-names></name><name><surname>Marchioni</surname><given-names>L</given-names></name><name><surname>Bartoli</surname><given-names>TA</given-names></name><etal/></person-group><article-title>National Institute for the Infectious Diseases &#x0201c;L. Spallanzani&#x0201d; IRCCS. Recommendations for COVID-19 clinical management</article-title><source>Infect Dis Rep</source><year>2020</year><pub-id pub-id-type="doi">10.4081/idr.2020.8543</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">World Health Organization (2020) Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-eng.pdf">https://apps.who.int/iris/bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-eng.pdf</ext-link>. Accessed 22 Mar 2020.</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro</article-title><source>Cell Discov</source><year>2020</year><volume>6</volume><issue>16</issue><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1038/s41421-020-0156-0</pub-id><pub-id pub-id-type="pmid">31934347</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrezenmeier</surname><given-names>E</given-names></name><name><surname>D&#x000f6;rner</surname><given-names>T</given-names></name></person-group><article-title>Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology</article-title><source>Nat Rev Rheumatol</source><year>2020</year><volume>16</volume><fpage>155</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1038/s41584-020-0372-x</pub-id><pub-id pub-id-type="pmid">32034323</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolain</surname><given-names>JM</given-names></name><name><surname>Colson</surname><given-names>P</given-names></name><name><surname>Raoult</surname><given-names>D</given-names></name></person-group><article-title>Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century</article-title><source>Int J Antimicrob Agents</source><year>2007</year><volume>30</volume><fpage>297</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2007.05.015</pub-id><pub-id pub-id-type="pmid">17629679</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies</article-title><source>Biosci Trends</source><year>2020</year><volume>14</volume><issue>1</issue><fpage>72</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.5582/bst.2020.01047</pub-id><pub-id pub-id-type="pmid">32074550</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P</given-names></name><name><surname>Lagier</surname><given-names>JC</given-names></name><name><surname>Parola</surname><given-names>P</given-names></name><name><surname>Hoang</surname><given-names>VT</given-names></name><name><surname>Meddeb</surname><given-names>L</given-names></name><name><surname>Mailhe</surname><given-names>M</given-names></name><etal/></person-group><article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title><source>Int J Antimicrob Agents</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105949</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>WZ</given-names></name></person-group><article-title>Repositioning chloroquine as ideal antiviral prophylactic against COVID-19-time is now</article-title><source>Preprints</source><year>2020</year><pub-id pub-id-type="doi">10.20944/preprints202003.0279.v1</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group><article-title>Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China</article-title><source>Intensive Care Med</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s00134-020-05991-x</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>P</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Sanchez</surname><given-names>E</given-names></name><name><surname>Tattersall</surname><given-names>RS</given-names></name><name><surname>Manson</surname><given-names>JJ</given-names></name></person-group><article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title><source>Lancet</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30628-0</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Xiong</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients</article-title><source>Preprints</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.02.29.20029520</pub-id></element-citation></ref></ref-list></back></article>